Balixafortide
Also known as: POL6326
An investigational cyclic peptide CXCR4 antagonist studied with eribulin in breast cancer. Not approved; the phase 3 FORTRESS trial failed in 2021.
Last updated
Mechanism of Action
Balixafortide is a synthetic cyclic peptide, built on a protein-epitope-mimetic scaffold, that blocks the CXCR4 chemokine receptor. CXCR4 signaling through its ligand CXCL12 is involved in tumor cell survival, metastasis and retention of cells in protective niches such as the bone marrow. Blocking it was intended to make tumor cells more sensitive to chemotherapy; it also mobilizes hematopoietic stem cells.
- Half-life
- Not well established
- Administration Routes
- Intravenous
- Research Status
- Clinical
Reported Benefits
- Studied with eribulin in HER2-negative metastatic breast cancer
- Phase 1 data showed tolerability and responses in heavily pretreated patients
- Mobilized stem cells in healthy volunteers (dose-escalation study)
Potential Side Effects
- Infusion-related reactions
- Neutropenia and fatigue when combined with eribulin
- Investigational: safety profile limited to trial data
Common Dosing
No approved dose; trial regimens used intravenous infusions in combination with eribulin chemotherapy. It is not available outside clinical trials.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Investigational: not established
No documented stacking partners for Balixafortide yet.